Vicuron Pharmaceuticals Announces Departure of Chief Operating Officer
March 17 2004 - 4:30PM
PR Newswire (US)
Vicuron Pharmaceuticals Announces Departure of Chief Operating
Officer KING OF PRUSSIA, Pa., March 17 /PRNewswire-FirstCall/ --
Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today
announced that Claudio Quarta, Ph.D., Chief Operating Officer is
leaving the company to pursue other opportunities. "Claudio has
made an important contribution to Vicuron Pharmaceuticals from the
original research collaboration with Biosearch Italia through our
successful merger which created a transatlantic company focused on
the discovery and development of novel anti-infectives," said
George F. Horner III, Vicuron's president and chief executive
officer. "His efforts have helped lay the ground-work for us to
commercialize our anti-infective portfolio in the U.S. and Europe.
We wish him well in his new endeavors." Dr. Quarta's former direct
reports Giorgio Mosconi, M.D., Senior Vice President of Business
Development, Robert Radie, Senior Vice President of Sales and Lyn
Wiesinger, Senior Vice President of Marketing and Market
Development will now report directly to Mr. Horner. About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients in North America and major
countries in Europe. The company has filed a New Drug Application
with the U.S. Food and Drug Administration for its lead product,
anidulafungin, a novel antifungal agent. The company's other lead
product, dalbavancin, a novel intravenous antibiotic for the
treatment of serious Gram-positive infections, is in Phase III
clinical trials. The company's versatile research engine integrates
industry-leading expertise in functional genomics, natural products
discovery, mechanism-based drug design and combinatorial and
medicinal chemistry. These approaches are yielding promising novel
and next-generation compounds, many of which are in the later
stages of preclinical development. In addition, the company has
research and development collaborations with leading pharmaceutical
companies, such as Pfizer and Novartis. Forward-Looking Statements
This news release contains forward-looking statements that predict
or describe future events or trends. The matters described in these
forward-looking statements are subject to known and unknown risks,
uncertainties and other unpredictable factors, many of which are
beyond Vicuron's control. Vicuron faces many risks that could cause
its actual performance to differ materially from the results
predicted by its forward-looking statements, including the
possibilities that the U.S. Securities and Exchange Commission may
delay declaring Vicuron's registration statement effective, if at
all, clinical trials and the results thereof might be delayed, that
the timing of the filing of any new drug application might be
delayed, that subsequent clinical trials might indicate that a
product candidate is unsafe or ineffective, that any filed new drug
application may not be approved, thatongoing proprietary and
collaborative research might not occur or yield useful results,
that a third party may not be willing to license our product
candidates on terms acceptable to us or at all, that competitors
might develop superior substitutes fortheir products or market them
more effectively, that a sales force may not be developed as
contemplated and that one or more of its product candidates may not
be commercialized successfully. The reports that Vicuron files with
the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is
subject. Because of those risks, Vicuron's actual results,
performance or achievements may differ materially from the results,
performance or achievements contemplated by its forward-looking
statement. The information set forth in this news release
represents management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in this news release. DATASOURCE:
Vicuron Pharmaceuticals, Inc. CONTACT: E. Blair Schoeb of Burns
McClellan Inc., +1-415-362-5018, or , or Ian McConnell, Ph.D of
WeissCom Partners, +1-610-205-2312, or , both for Vicuron
Pharmaceuticals Inc.; or Dov A. Goldstein, M.D., of Vicuron
Pharmaceuticals Inc., +1-212-213-0006, or Web site:
http://www.vicuron.com/
Copyright